Key Findings:  Although the studies are scarce, CBD seems to be effective on treating dystonic movements, both primary and secondary. It is noteworthy that in some cases, particularly concerning multiple sclerosis and HD, the clinical beneficial effects are observed only when CBD is combined with Δ9-THC in a 1:1 ratio (Sativex). In fact, these therapeutic effects are probably due to Δ9-THC, since they are also seen with other cannabinoid agonists . Nonetheless, CBD is shown to diminish the Δ9-THC unwanted effects, such as sedation, memory impairments, and psychosis. Data suggest that CBD's might have a preventive role rather than a therapeutic one in PD. The molecular mechanisms associated with CBD's improvement of motor disorders are likely multifaceted. Data show that it might depend on CBD's actions on 5-HT1A, CB1, CB2, and/or PPARγ receptors.
Type of Study:  Meta-analysis
Study Result:  Positive
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified), Pharma THC:CBD
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype II, Chemotype I, Chemotype III